伊利诺伊州北芝加哥 - 艾伯维公司（纽约证券交易所代码：ABBV）和Gedeon Richter Plc.宣布达成协议，共同发现和开发治疗神经精神疾病的新疗法。这项合作建立在近20年的合作伙伴关系基础之上，该合作关系已经产生了中枢神经系统疗法，包括cariprazine（VRAYLAR® / REAGILA®）和研究中的药物ABBV-932。

AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...

Related: Analyst revises AbbVie stock price target on drug-sale estimates Sales eroded, however, as Humira faced competition ...

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.

On CNBC's "Mad Money Lightning Round," Jim Cramer said AbbVie Inc. (NYSE:ABBV) is doing "very, very well." However, he added that Abbott Laboratories (NYSE:ABT) remains his favorite in the group right ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.